• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠-肝轴与非酒精性脂肪性肝病:由肠道微生物群精心策划的功能障碍恶性循环

Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome.

作者信息

Pezzino Salvatore, Sofia Maria, Faletra Gloria, Mazzone Chiara, Litrico Giorgia, La Greca Gaetano, Latteri Saverio

机构信息

Department of Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Cannizzaro Hospital, University of Catania, 95126 Catania, Italy.

出版信息

Biology (Basel). 2022 Nov 6;11(11):1622. doi: 10.3390/biology11111622.

DOI:10.3390/biology11111622
PMID:36358323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9687983/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a prevalent, multifactorial, and poorly understood liver disease with an increasing incidence worldwide. NAFLD is typically asymptomatic and coupled with other symptoms of metabolic syndrome. The prevalence of NAFLD is rising in tandem with the prevalence of obesity. In the Western hemisphere, NAFLD is one of the most prevalent causes of liver disease and liver transplantation. Recent research suggests that gut microbiome dysbiosis may play a significant role in the pathogenesis of NAFLD by dysregulating the gut-liver axis. The so-called "gut-liver axis" refers to the communication and feedback loop between the digestive system and the liver. Several pathological mechanisms characterized the alteration of the gut-liver axis, such as the impairment of the gut barrier and the increase of the intestinal permeability which result in endotoxemia and inflammation, and changes in bile acid profiles and metabolite levels produced by the gut microbiome. This review will explore the role of gut-liver axis disruption, mediated by gut microbiome dysbiosis, on NAFLD development.

摘要

非酒精性脂肪性肝病(NAFLD)是一种普遍存在、多因素且了解不足的肝脏疾病,在全球范围内发病率不断上升。NAFLD通常无症状,并伴有代谢综合征的其他症状。NAFLD的患病率与肥胖症的患病率同步上升。在西半球,NAFLD是肝病和肝移植最常见的原因之一。最近的研究表明,肠道微生物群失调可能通过调节肠道-肝脏轴,在NAFLD的发病机制中发挥重要作用。所谓的“肠道-肝脏轴”是指消化系统与肝脏之间的通讯和反馈回路。几种病理机制表征了肠道-肝脏轴的改变,例如肠道屏障受损和肠道通透性增加,这会导致内毒素血症和炎症,以及肠道微生物群产生的胆汁酸谱和代谢物水平的变化。本综述将探讨由肠道微生物群失调介导的肠道-肝脏轴破坏在NAFLD发展中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/4074937795aa/biology-11-01622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/04fb574983a8/biology-11-01622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/52f6235fbc6c/biology-11-01622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/4074937795aa/biology-11-01622-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/04fb574983a8/biology-11-01622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/52f6235fbc6c/biology-11-01622-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86f0/9687983/4074937795aa/biology-11-01622-g003.jpg

相似文献

1
Gut-Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome.肠-肝轴与非酒精性脂肪性肝病:由肠道微生物群精心策划的功能障碍恶性循环
Biology (Basel). 2022 Nov 6;11(11):1622. doi: 10.3390/biology11111622.
2
The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.肠-肝轴在肠道微生物群失调相关的非酒精性脂肪性肝病和非酒精性脂肪性肝病-肝癌中的作用
Biomedicines. 2022 Feb 23;10(3):524. doi: 10.3390/biomedicines10030524.
3
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.非酒精性脂肪性肝病与肠道微生物失调:潜在机制和肠道微生物介导的治疗策略。
Rev Endocr Metab Disord. 2023 Dec;24(6):1189-1204. doi: 10.1007/s11154-023-09843-z. Epub 2023 Oct 16.
4
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD).肠道微生物组与非酒精性脂肪性肝病(NAFLD)之间的联系。
Cell Mol Life Sci. 2019 Apr;76(8):1541-1558. doi: 10.1007/s00018-019-03011-w. Epub 2019 Jan 25.
5
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
6
The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.肠道微生物组和饮食在非酒精性脂肪性肝病发病机制中的作用。
Clin Mol Hepatol. 2021 Jan;27(1):22-43. doi: 10.3350/cmh.2020.0129. Epub 2020 Dec 10.
7
The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.基于肠-肝轴的分子和机制见解:改善非酒精性脂肪性肝病(NAFLD)的营养靶点。
Int J Mol Sci. 2020 Apr 26;21(9):3066. doi: 10.3390/ijms21093066.
8
Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.特定代谢辅因子组合可调节与非酒精性脂肪性肝病相关的微生物失调和肠道屏障功能障碍。
Int J Mol Sci. 2022 Nov 8;23(22):13675. doi: 10.3390/ijms232213675.
9
Non-alcoholic fatty liver and the gut microbiota.非酒精性脂肪肝与肠道微生物群
Mol Metab. 2016 Jun 14;5(9):782-94. doi: 10.1016/j.molmet.2016.06.003. eCollection 2016 Sep.
10
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.肠源性内毒素血症和肠道屏障在脂肪性肝病中的作用。
J Gastrointest Surg. 2022 Mar;26(3):671-683. doi: 10.1007/s11605-021-05188-7. Epub 2021 Nov 3.

引用本文的文献

1
Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends.代谢功能障碍相关脂肪性肝病(MASLD)中的脂肪因子和肝脏因子:现状与发展趋势
Biomedicines. 2025 Jul 30;13(8):1854. doi: 10.3390/biomedicines13081854.
2
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).代谢功能障碍相关脂肪性肝病(MASLD)时代非酒精性脂肪性肝病(NAFLD)的病理演变与内科管理
Cureus. 2025 Jun 29;17(6):e86963. doi: 10.7759/cureus.86963. eCollection 2025 Jun.
3

本文引用的文献

1
Microbiome-derived ethanol in nonalcoholic fatty liver disease.微生物组衍生的乙醇在非酒精性脂肪性肝病中的作用。
Nat Med. 2022 Oct;28(10):2100-2106. doi: 10.1038/s41591-022-02016-6. Epub 2022 Oct 10.
2
Local and systemic effects of microbiome-derived metabolites.微生物组衍生代谢物的局部和全身效应。
EMBO Rep. 2022 Oct 6;23(10):e55664. doi: 10.15252/embr.202255664. Epub 2022 Aug 29.
3
A potential link between plasma short-chain fatty acids, TNF-α level and disease progression in non-alcoholic fatty liver disease: A retrospective study.
MASLD development: From molecular pathogenesis toward therapeutic strategies.
代谢相关脂肪性肝病的发展:从分子发病机制到治疗策略
Chin Med J (Engl). 2025 Aug 5;138(15):1807-1824. doi: 10.1097/CM9.0000000000003629. Epub 2025 Jul 10.
4
Role of gut-brain axis dysregulation in the pathogenesis of non-alcoholic fatty liver disease: mechanisms and therapeutic implications.肠-脑轴失调在非酒精性脂肪性肝病发病机制中的作用:机制与治疗意义
Am J Transl Res. 2025 May 15;17(5):3276-3292. doi: 10.62347/ZWSR4476. eCollection 2025.
5
SANK70258 supplementation improves growth performance, gut health, and liver function in growing pigs.补充SANK70258可改善生长猪的生长性能、肠道健康和肝功能。
Front Vet Sci. 2025 May 27;12:1537913. doi: 10.3389/fvets.2025.1537913. eCollection 2025.
6
Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.肠-肝轴:肠道微生物群及其代谢产物在代谢功能障碍相关脂肪性肝病进展中的作用
Gut Liver. 2025 May 8. doi: 10.5009/gnl240539.
7
Mapping Research Trends in Alcoholic Liver Disease: A Bibliometric Perspective.从文献计量学角度看酒精性肝病的研究趋势图谱
Dig Dis Sci. 2025 Jul;70(7):2244-2245. doi: 10.1007/s10620-025-08948-6. Epub 2025 Mar 10.
8
Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease.李对代谢相关脂肪性肝病肝肠损伤的保护作用。
Nutrients. 2024 Nov 1;16(21):3760. doi: 10.3390/nu16213760.
9
Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds.肥胖症和非酒精性脂肪性肝病的创新疗法:关于抗氧化剂、草药、植物化学物质和天然化合物的文献计量学研究
Heliyon. 2024 Aug 8;10(16):e35498. doi: 10.1016/j.heliyon.2024.e35498. eCollection 2024 Aug 30.
10
Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD).生酮饮食对非酒精性脂肪性肝病(NAFLD/MAFLD)的有益作用。
J Clin Med. 2024 Aug 17;13(16):4857. doi: 10.3390/jcm13164857.
血浆短链脂肪酸、TNF-α水平与非酒精性脂肪性肝病疾病进展之间的潜在联系:一项回顾性研究
Exp Ther Med. 2022 Jul 28;24(3):598. doi: 10.3892/etm.2022.11536. eCollection 2022 Sep.
4
Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota.法尼酯X受体、胆汁酸代谢与肠道微生物群
Metabolites. 2022 Jul 14;12(7):647. doi: 10.3390/metabo12070647.
5
Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy.微生物短链脂肪酸:一种调节过继性 T 细胞疗法的策略。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2021-004147.
6
Bile acids and sphingolipids in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的胆汁酸和神经鞘脂类。
Chin Med J (Engl). 2022 May 20;135(10):1163-1171. doi: 10.1097/CM9.0000000000002156.
7
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL).越来越多的证据表明极低密度脂蛋白(VLDL)具有病理性作用。
Int J Mol Sci. 2022 Apr 13;23(8):4300. doi: 10.3390/ijms23084300.
8
The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment.非酒精性脂肪性肝病和脂肪性肝炎中的NLRP3炎性小体:治疗靶点与治疗方法
Front Pharmacol. 2022 Mar 8;13:780496. doi: 10.3389/fphar.2022.780496. eCollection 2022.
9
The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.肠-肝轴在肠道微生物群失调相关的非酒精性脂肪性肝病和非酒精性脂肪性肝病-肝癌中的作用
Biomedicines. 2022 Feb 23;10(3):524. doi: 10.3390/biomedicines10030524.
10
Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.非酒精性脂肪性肝病(NAFLD):病理生理学、临床管理和减肥效果的综述。
BMC Endocr Disord. 2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1.